^
    Back
    Association details:
    Biomarker:CCDC85A-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Cell Mol Med
    Title:

    Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report

    Published date:
    09/14/2022
    Excerpt:
    A 55-year-old Chinese man with a right lung mass and lymph node metastasis (T4N3M0 IIIB) was diagnosed with lung adenocarcinoma...we found a rare CCDC85A-ALK fusion. The patient received alectinib, which had marked efficacy.
    DOI:
    10.1111/jcmm.17520